EXHIBIT 4.7
UNIPHY HEALTHCARE, INC.
AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE
AGREEMENT
This AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT
(the "Amended and Restated Right of First Refusal and Co-Sale Agreement") is
made as of this 25th day of June, 1999, by and among UNIPHY HEALTHCARE, INC., a
Tennessee corporation (the "Company"), and those Persons identified on Exhibit A
attached hereto (collectively, the "Investors" and each individually an
"Investor").
RECITALS
WHEREAS, those Investors so identified on Exhibit A attached hereto are
common shareholders of the Company who either (1) formerly held shares of
preferred stock of the Company (the "UniPhy Preferred Shareholders") or (2) are
key employees of the Company who received founders common stock of the Company
(the "UniPhy Founders"), and who are parties to either the Right of First
Refusal and Co-Sale Agreement, dated April 16, 1998, or the Right of First
Refusal and Co-Sale Agreement, dated March 13, 1996 (the "Co-Sale Agreements");
and
WHEREAS, those Investors so identified on Exhibit A attached hereto are
current key shareholders (the "ARC Key Shareholders") of Ambulatory Resource
Centres, Inc., a Tennessee corporation ("ARC"), who, following the Merger (as
defined below), will become common shareholders of the Company; and
WHEREAS, the Company, UniPhy Acquisition Sub, Inc., a Tennessee
corporation and a wholly-owned subsidiary of the Company ("UniPhy Sub"), and ARC
are parties to an Agreement and Plan of Merger, dated June 8, 1999 (the "Merger
Agreement"), whereby UniPhy Sub shall merge with and into ARC, each outstanding
share of common stock of ARC shall be converted into the right to receive 6.54
shares of common stock of the Company and ARC shall become a wholly-owned
subsidiary of the Company (the "Merger"); and
WHEREAS, it is a condition to the closing of the Merger pursuant to the
Merger Agreement that each of the parties hereto enter into this Amended and
Restated Right of First Refusal and Co-Sale Agreement; and
WHEREAS, each of the parties hereto shall receive a substantial benefit
from the closing of the Merger; and
WHEREAS, the UniPhy Preferred Shareholders and the UniPhy Founders
desire to amend and restate and to supersede in their entirety the Co-Sale
Agreements in the manner set forth herein; and
WHEREAS, the ARC Key Shareholders desire to join and be entitled to the
rights and subject to the obligations provided in the Co-Sale Agreements, as
amended and restated in this Amended and Restated Right of First Refusal and
Co-Sale Agreement.
NOW, THEREFORE, in consideration of the premises and for other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:
1. Definitions.
(a) "Co-Sale Stock" shall mean shares of the Common Stock (as
defined below) now owned or subsequently acquired by the Investors. The number
of shares of Co-Sale Stock owned by each Investor is set forth on Exhibit B,
which exhibit shall automatically be amended from time to time to reflect
changes in the number of shares owned by the Investors.
(b) "Common Stock" shall mean the common stock, no par value, of
the Company.
2. Sales by Investors.
(a) Notice Requirement. If any Investor proposes to sell or
transfer any shares of Co-Sale Stock, then such Investor shall promptly give
written notice (the "Notice") simultaneously to the Company and to each of the
non-selling Investors (the "Non-Selling Investors") at least thirty (30) days
prior to the closing of such sale or transfer. The Notice shall describe in
reasonable detail the proposed sale or transfer including, without limitation,
the number of shares of Co-Sale Stock to be sold or transferred, the nature of
such sale or transfer, the consideration to be paid, and the name and address of
each prospective purchaser or transferee. In the event that the sale or transfer
is being made pursuant to the provisions of Sections 3(a) and 3 (b) hereof, the
Notice shall state under which section the sale or transfer is being made.
(b) Company's Right of First Refusal. For a period of ten (10)
days following receipt of any Notice described in Section 2(a), the Company
shall have the right to purchase all or a portion of the Co-Sale Stock subject
to such Notice on the same terms and conditions as set forth therein. The
Company's purchase right shall be exercised by written notice signed by an
officer of the Company and delivered to the selling Investor (with a copy to
each Non-Selling Investor) with a check for payment for the Co-Sale Stock being
purchased.
(c) Non-Selling Investors' Right of First Refusal. If the Company
does not purchase all of the Co-Sale Stock available pursuant to its rights
under Section 2(b) within the period set forth therein, each Non-Selling
Investor shall then have the right, exercisable upon written notice to the
Investor (with a copy to each other Non-Selling Investor) within twenty (20)
days of the date of the original Notice described in Section 2(a), to purchase
its pro rata share of the Co-Sale Stock subject to the
2
Notice (less shares purchased by the Company pursuant to Section 2(b)) on the
same terms and conditions.
i. Each Non-Selling Investor's pro rata share shall be
equal to the product obtained by multiplying (x) the aggregate number of shares
of Co-Sale Stock covered by the Notice (less shares purchased by the Company
pursuant to Section 2(b)) by (y) a fraction the numerator of which is the number
of shares of Co-Sale Stock owned by the Non-Selling Investor (on an
as-if-converted basis) at the time of the sale or transfer and the denominator
of which is the total number of shares of Co-Sale Stock owned by all of the
Non-Selling Investors (on an as-if-converted basis) at the time of the sale or
transfer.
ii. Each Non-Selling Investor shall have a right of over
allotment to purchase pursuant to the terms of this subsection 2(c) its pro rata
share of the Co-Sale Stock not purchased by the Company or other Non-Selling
Investors as provided for above.
(d) Non-Selling Investors' Co-Sale Right. Should the Non-Selling
Investors and/or the Company fail to exercise their respective rights to
purchase all of the shares of Co-Sale Stock described in the Notice issued
pursuant to Section 2(a) following the exercise or expiration of the rights of
purchase described in Sections 2(b) and 2(c), then each Non-Selling Investor
shall have the right, exercisable upon written notice to the selling Investor
within thirty (30) days of the date of the original Notice described in Section
2(a), to participate in such sale of Co-Sale Stock on the same terms and
conditions. Such notice shall indicate the number of shares of Common Stock such
Non-Selling Investor wishes to sell under his, her or its right to participate.
To the extent one or more of the Non-Selling Investors exercise such right of
participation in accordance with the terms and conditions set forth below, the
number of shares of Co-Sale Stock that the Investor may sell in the transaction
shall be correspondingly reduced.
i. Each Non-Selling Investor may sell all or any part of
that number of shares equal to the product obtained by multiplying (x) the
aggregate number of shares of Co-Sale Stock covered by the Notice (as reduced by
any purchases pursuant to Sections 2(b) or 2(c)) by (y) a fraction the numerator
of which is the number of shares of Common Stock owned by the Non-Selling
Investor at the time of the sale or transfer (on an as-if-converted basis) and
the denominator of which is the total number of shares of Common Stock owned by
the Investor and the Non-Selling Investors at the time of the sale or transfer
(on an as-if-converted basis).
ii. Each Non-Selling Investor who elects to participate
in the sale pursuant to this Section 2(d) (a "Participant") shall effect its
participation in the sale by promptly delivering to the Investor for transfer to
the prospective purchaser one or more certificates, properly endorsed for
transfer, which represent the type and number of shares of Common Stock which
such Participant elects to sell.
3
iii. The stock certificate or certificates that the
Participant delivers to the Investor pursuant to Section 2(d) shall be
transferred to the prospective purchaser in consummation of the sale of the
Common Stock pursuant to the terms and conditions specified in the Notice, and
the Investor shall concurrently therewith remit to such Participant that portion
of the sale proceeds to which such Participant is entitled by reason of its
participation in such sale. To the extent that any prospective purchaser or
purchasers prohibits such assignment or otherwise refuses to purchase shares or
other securities from a Participant exercising its rights of co-sale hereunder,
the Investor shall not sell to such prospective purchaser or purchasers any
Co-Sale Stock unless and until, simultaneously with such sale, the Investor
shall purchase such shares or other securities from such Participant on the same
terms and conditions specified in the Notice.
(e) If none of the Non-Selling Investors elect to participate in
the sale of the Co-Sale Stock subject to the Notice, the Investor may, not later
than sixty (60) days following delivery to the Company of the Notice, enter into
an agreement providing for the closing of the transfer of the Co-Sale Stock
covered by the Notice within thirty (30) days of such agreement on terms and
conditions not materially more favorable to the transferor than those described
in the Notice. Any proposed transfer on terms and conditions materially more
favorable than those described in the Notice, as well as any subsequent proposed
transfer of any of the Co-Sale Stock by the Investor, shall again be subject to
the right of first refusal and co-sale rights of the Non-Selling Investors and
shall require compliance with the procedures described in this Section 2.
3. Exempt Transfers.
(a) Notwithstanding the foregoing, the rights of first refusal and
the co-sale rights of the Company and the Non-Selling Investors (the "Rights")
shall not apply to (i) any transfer or transfers by any Investor which in the
aggregate amount to no more than ten percent (10%) of Co-Sale Stock held by all
Investors as of the date of any proposed transfer, (ii) any pledge of Co-Sale
Stock made pursuant to a bona fide loan transaction with a financial institution
that creates a mere security interest, (iii)any transfer to the ancestors,
descendants or spouse of a Investor or to trusts for the benefit of such persons
or such Investor, (iv) any transfer to its partners or members by a Investor
that is a partnership or limited liability company; (v) any transfer to its
affiliate by a Investor that is a corporation, or (vi) any bona fide gift;
provided that in the event of any transfer made pursuant to one of the
exemptions provided by clauses (ii), (iii), (iv), (v) and (vi), (A) such
Investor shall inform the Company and the Non-Selling Investors of such pledge,
transfer or gift prior to effecting it and (B) the pledgee, transferee or donee
shall furnish the Company and the Non-Selling Investors with a written agreement
to be bound by and comply with all provisions of Section 2. Except with respect
to Co-Sale Stock transferred under clause (i) above (which Co-Sale Stock shall
no longer be subject to the co-sale rights of the Non-Selling Investors), such
transferred Co-Sale Stock shall remain "Co-Sale Stock" hereunder, and such
pledgee, transferee or donee shall be treated as a
4
"Investor" for purposes of this Amended and Restated Right of First Refusal and
Co-Sale Agreement.
(b) Notwithstanding the foregoing, the Rights with respect to
Co-Sale Stock held by the UniPhy Founders shall terminate upon the closing of a
firm commitment underwritten public offering of the Common Stock pursuant to an
effective registration statement under the Securities Act of 1933, as amended,
at a price per share of not less than $7.00 (as adjusted for any stock
dividends, combinations or splits with respect to such shares effected after the
date of this Amended and Restated Right of First Refusal and Co-Sale Agreement)
and gross proceeds of not less than $20,000,000 (an "Initial Offering"); and
(ii) the Rights with respect to Co-Sale Stock held by the UniPhy Preferred
Shareholders and the ARC Key Shareholders shall terminate upon the earlier of an
Initial Offering or the fifth anniversary of the date of this Amended and
Restated Right of First Refusal and Co-Sale Agreement.
(c) This Amended and Restated Right of First Refusal and Co-Sale
Agreement is subject to, and shall in no manner limit the right which the
Company may have to repurchase securities from the UniPhy Founders provided that
any such repurchase by the Company shall remain subject to any limitations in
the Charter of the Company.
4. Prohibited Transfers.
(a) In the event that a Investor should sell any Co-Sale Stock in
contravention of the rights of first refusal of the Company and the Non-Selling
Investors and the co-sale rights of each Non-Selling Investor under this Amended
and Restated Right of First Refusal and Co-Sale Agreement (a "Prohibited
Transfer"), each Investor, in addition to such other remedies as may be
available at law, in equity or hereunder, shall have the put option provided
below, and such Investor shall be bound by the applicable provisions of such
option.
(b) In the event of a Prohibited Transfer, each Non-Selling
Investor shall have the right to sell to such Investor the type and number of
shares of Common Stock equal to the number of shares each Non-Selling Investor
would have been entitled to transfer to the purchaser under Section 2(c) hereof
had the Prohibited Transfer been effected pursuant to and in compliance with the
terms hereof. Such sale shall be made on the following terms and conditions:
i. The price per share at which the shares are to be
sold to such Investor shall be equal to the price per share paid by the
purchaser to the Investor in such Prohibited Transfer. The Investor shall also
reimburse each Non-Selling Investor for any and all fees and expenses, including
legal fees and expenses, incurred pursuant to the exercise or the attempted
exercise of the Non-Selling Investor's rights under Section 2(c).
ii. Within ninety (90) days after the later of the dates
on which the Non-Selling Investor (a) received notice of the Prohibited Transfer
or (b) otherwise
5
became aware of the Prohibited Transfer, each Non-Selling Investor shall, if
exercising the option created hereby, deliver to the Investor the certificate or
certificates representing shares to be sold, each certificate to be properly
endorsed for transfer.
iii. The Investor shall, upon receipt of the certificate
or certificates for the shares to be sold by an Non-Selling Investor, pursuant
to this Section 4(b), pay the aggregate purchase price therefor and the amount
of reimbursable fees and expenses, as specified in Section 4(b)(i), in cash or
by other means acceptable to the Non-Selling Investor.
(c) Notwithstanding the foregoing, any attempt by a Investor to
transfer Co-Sale Stock in violation of Section 2(a) hereof shall be voidable at
the option of the Company, and any attempt by a Investor to transfer Co-Sale
Stock in violation of Section 2(b) or 2(c) hereof shall be voidable at the
option of a majority in interest of the Non-Selling Investors if, with respect
to a transfer in violation of Section 2(c), the Non-Selling Investors do not
elect to exercise the put option set forth in this Section 4, and the Company
agrees it will not effect such a transfer nor will it treat any alleged
transferee as the Investor of such shares without the written consent of a
majority in interest of the Non-Selling Investors.
5. Legend.
(a) Each certificate representing shares of Co-Sale Stock now or
hereafter owned by the Investors or issued to any person in connection with a
transfer pursuant to Section 3(a) hereof shall be endorsed with the following
legend:
"THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES
REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND
CONDITIONS OF A CERTAIN RIGHT OF FIRST REFUSAL AND CO-SALE
AGREEMENT BY AND AMONG THE STOCKHOLDER, THE COMPANY AND
CERTAIN HOLDERS OF STOCK OF THE COMPANY. COPIES OF SUCH
AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE
SECRETARY OF THE COMPANY."
(b) The Investors agree that the Company may instruct its transfer
agent to impose transfer restrictions on the shares represented by certificates
bearing the legend referred to in Sections(a) above to enforce the provisions of
this Amended and Restated Right of First Refusal and Co-Sale Agreement and the
Company agrees to promptly do so. The legend shall be removed upon termination
of this Amended and Restated Right of First Refusal and Co-Sale Agreement.
6
6. Miscellaneous.
(a) Conditions to Exercise of Rights. Exercise of the Rights under
this Amended and Restated Right of First Refusal and Co-Sale Agreement shall be
subject to and conditioned upon, and each Investor and the Company shall use
their best efforts to assist, each other party hereto in, compliance with
applicable laws.
(b) Governing Law. This Amended and Restated Right of First
Refusal and Co-Sale Agreement, and the rights of the parties hereto, shall be
governed by and construed under the laws of the State of California.
(c) Amendment. Any provision of this Amended and Restated Right of
First Refusal and Co-Sale Agreement may be amended and the observance thereof
may be waived (either generally or in a particular instance and either
retroactively or prospectively), only by the written consent of (i) as to the
Company, only by the Company, (ii) as to the UniPhy Preferred Shareholders and
the ARC Key Shareholders, by persons holding at least at least seventy-five
percent (75%) in interest of the aggregate number of shares of Common Stock held
by the UniPhy Preferred Shareholders and the ARC Key Shareholders and their
assignees, pursuant to Section 6(d) hereof; and (iii) as to the UniPhy Founders,
by persons holding at least seventy-five percent (75%) in interest of the
aggregate number of shares of Common Stock held by the UniPhy Founders and their
assignees, pursuant to Section 6(d) hereof. Any amendment or waiver effected in
accordance with clauses (i) and (ii) of this Section 6(c) shall be binding upon
each Investor, its successors and assigns, and the Company.
(d) Assignment of Rights. This Amended and Restated Right of First
Refusal and Co-Sale Agreement constitutes the entire agreement between the
parties relative to the specific subject matter hereof. Any previous agreement
among the parties relative to the specific subject matter hereof is superseded
by this Amended and Restated Right of First Refusal and Co-Sale Agreement. This
Amended and Restated Right of First Refusal and Co-Sale Agreement and the rights
and obligations of the parties hereunder shall inure to the benefit of, and be
binding upon, their respective successors, assigns and legal representatives.
(e) Term. This Amended and Restated Right of First Refusal and
Co-Sale Agreement shall terminate upon the closing of an Initial Offering.
(f) Ownership. Each Investor represents and warrants that such
Investor is the sole legal and beneficial owner of those shares of Co-Sale Stock
currently held by such Investor subject to this Amended and Restated Right of
First Refusal and Co-Sale Agreement and that no other person has any interest
(other than a community property interest) in such shares.
(g) Notices. All notices required or permitted hereunder shall be
in writing and shall be deemed effectively given: (i) upon personal delivery to
the party to be notified, (ii) when sent by confirmed telex or facsimile if sent
during normal business
7
hours of the recipient; if not, then on the next business day, (iii) five (5)
days after having been sent by registered or certified mail, return receipt
requested, postage prepaid, or (iv) one (1) day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the party to be
notified at the address as set forth on the signature page hereof or at such
other address as such party may designate by ten (10) days advance written
notice to the other parties hereto.
(h) Severability. In the event one or more of the provisions of
this Amended and Restated Right of First Refusal and Co-Sale Agreement should,
for any reason, be held to be invalid, illegal or unenforceable in any respect,
such invalidity, illegality, or unenforceability shall not affect any other
provisions of this Amended and Restated Right of First Refusal and Co-Sale
Agreement, and this Amended and Restated Right of First Refusal and Co-Sale
Agreement shall be construed as if such invalid, illegal or unenforceable
provision had never been contained herein.
(i) Attorneys' Fees. In the event that any dispute among the
parties to this Agreement should result in litigation, the prevailing party in
such dispute shall be entitled to recover from the losing party all fees, costs
and expenses of enforcing any right of such prevailing party under or with
respect to this Agreement, including without limitation, such reasonable fees
and expenses of attorneys and accountants, which shall include, without
limitation, all fees, costs and expenses of appeals.
(j) Counterparts. This Amended and Restated Right of First Refusal
and Co-Sale Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and
the same instrument.
(k) Entire Agreement. This Amended and Restated Right of First
Refusal and Co-Sale Agreement constitutes the entire agreement among the parties
hereto with respect to the matters set forth herein, and it supersedes all prior
oral or written agreements, commitments or understandings with respect to the
matters provided for herein, without limitation, the Right of First Refusal and
Co-Sale Agreements, dated April 16, 1998 and March 13, 1996, respectively.
8
The foregoing Amended and Restated Right of First Refusal and Co-Sale
Agreement is hereby executed as of the date first above written.
COMPANY:
UNIPHY HEALTHCARE, INC.
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇.
-------------------------------------------
By: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇.
---------------------------------------
Its: President and Chief Executive Officer
--------------------------------------
INVESTORS:
UNIPHY PREFERRED SHAREHOLDERS:
ABS CAPITAL PARTNERS, L.P.
/s/ ABS Partners, LP
-------------------------------------------
By: ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
---------------------------------------
Title: General Partner
------------------------------------
/s/ ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
/s/ ▇▇▇▇▇ ▇. ▇▇▇▇
-------------------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇
/s/ ▇▇▇▇ ▇▇▇▇▇
-------------------------------------------
▇▇▇▇ ▇▇▇▇▇
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇.
-------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇.
/s/ R. ▇▇▇▇ ▇▇▇▇▇▇▇
-------------------------------------------
R. ▇▇▇▇ ▇▇▇▇▇▇▇
SIGNATURE PAGE TO AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE
AGREEMENT
/s/ ▇▇▇ ▇▇▇▇▇▇▇
-------------------------------------------
▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇▇▇ INVESTMENT PARTNERSHIP II
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇.
-------------------------------------------
By: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇.
---------------------------------------
Title:
------------------------------------
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
PACIFIC VENTURE GROUP, L.P.
By: PVG Equity Partner, L.L.C.,
its General Partner
/s/ ▇▇▇ ▇. ▇▇▇▇▇▇
-------------------------------------------
By: ▇▇▇ ▇. ▇▇▇▇▇▇
Title: Member
PVG ASSOCIATES, L.P.
By: PVG Equity Partner, L.L.C.,
its General Partner
/s/ ▇▇▇ ▇. ▇▇▇▇▇▇
-------------------------------------------
By: ▇▇▇ ▇. ▇▇▇▇▇▇
Title: Member
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
/s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇
SIGNATURE PAGE TO AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE
AGREEMENT
/s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇▇ ▇▇▇▇▇▇
ARC KEY SHAREHOLDERS:
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ FOUNDATION
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-------------------------------------------
By: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
---------------------------------------
Title: President
------------------------------------
/s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇▇
FIRST AVENUE PARTNERS, L.P.
/s/ Front Street, LLC, General Partner
-------------------------------------------
By: ▇▇▇▇▇ ▇. ▇▇▇▇▇
---------------------------------------
Title: Managing Member
------------------------------------
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
/s/ J. ▇▇▇▇▇▇▇ ▇▇▇▇▇
-------------------------------------------
J. ▇▇▇▇▇▇▇ ▇▇▇▇▇
HEALTH TECH AFFILIATES, INC.
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-------------------------------------------
By: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
---------------------------------------
Title: Vice President
------------------------------------
HLM/CB FUND, L.P.
-------------------------------------------
By:
---------------------------------------
Title:
------------------------------------
SIGNATURE PAGE TO AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE
AGREEMENT
HLM PARTNERS VII, L.P.
By:
---------------------------------------
Title:
------------------------------------
/s/ W. ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
-------------------------------------------
W. ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇, INC.
By:
---------------------------------------
Title:
------------------------------------
/s/ B. Max Lauderdale
-------------------------------------------
B. Max Lauderdale
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇.
-------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇.
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇
/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇ ▇▇▇▇▇▇
../s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇▇
/s/ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇
-------------------------------------------
▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇
SIGNATURE PAGE TO AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE
AGREEMENT
RICHLAND VENTURES II, L.P.
/s/ ▇▇▇▇ ▇▇▇▇▇▇▇
-------------------------------------------
By: ▇▇▇▇ ▇▇▇▇▇▇▇
---------------------------------------
Title: Managing Partner
------------------------------------
/s/ ▇▇▇ ▇. ▇▇▇▇▇▇
-------------------------------------------
▇▇▇ ▇. ▇▇▇▇▇▇
SOUTH ATLANTIC PRIVATE EQUITY FUND IV (QP), LIMITED PARTNERSHIP
By: South Atlantic Private Equity Partners IV, Limited Partnership
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
----------------------------------
By: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------
Title: General Partner
---------------------------
SOUTH ATLANTIC PRIVATE EQUITY FUND IV, L.P.
By: South Atlantic Private Equity Partners IV, Limited Partnership
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
----------------------------------
By: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------
Title: General Partner
---------------------------
/s/ ▇▇▇ ▇▇▇▇▇▇, ▇▇.
-------------------------------------------
▇▇▇ ▇▇▇▇▇▇, ▇▇.
/s/ ▇▇▇▇▇▇▇ ▇.▇. ▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇▇ V.B. ▇▇▇▇
▇▇ TWO, L.P.
-------------------------------------------
By:
---------------------------------------
Title:
------------------------------------
/s/ ▇▇▇▇▇ ▇. ▇▇▇▇, III
-------------------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇, III
SIGNATURE PAGE TO AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE
AGREEMENT
UNIPHY FOUNDERS:
/s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇ ▇▇▇▇▇▇▇▇
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
THE ▇▇▇▇▇▇▇ IRREVOCABLE TRUST,
▇▇▇ ▇▇▇▇▇▇▇, TRUSTEE
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇.
-------------------------------------------
By: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇.
---------------------------------------
Title:
------------------------------------
/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
/s/ H. ▇▇▇▇▇▇ ▇▇▇▇▇▇ III
-------------------------------------------
H. ▇▇▇▇▇▇ ▇▇▇▇▇▇ III
/s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇▇ ▇▇▇▇▇
/s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇▇ ▇▇▇▇▇
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-------------------------------------------
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
SIGNATURE PAGE TO AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE
AGREEMENT
EXHIBIT A
INVESTORS
UNIPHY PREFERRED SHAREHOLDERS
ABS Capital Partners, L.P.
▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
▇▇▇▇▇ ▇. ▇▇▇▇
▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, ▇▇.
R. ▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇▇▇ Investment Partnership II
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Pacific Venture Group, L.P.
PVG Associates, L.P.
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇
ARC KEY SHAREHOLDERS
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ Foundation
▇▇▇▇▇ ▇. ▇▇▇▇▇
First Avenue Partners, L.P.
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
J. ▇▇▇▇▇▇▇ ▇▇▇▇▇
Health Tech Affiliates, Inc.
HLM/CB Fund, L.P.
HLM Partners VII, L.P.
W. ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇, Inc.
B. Max Lauderdale
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇.
▇▇▇▇▇▇▇ ▇. ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇ ▇. ▇▇▇▇▇
▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇
Richland Ventures II, L.P.
▇▇▇ ▇. ▇▇▇▇▇▇
South Atlantic Private Equity Fund IV (QP)
South Atlantic Private Equity Fund IV, L.P.
▇▇▇ ▇▇▇▇▇▇, ▇▇.
▇▇▇▇▇▇▇ V.B. ▇▇▇▇
▇▇ Two, L.P.
▇▇▇▇▇ ▇. ▇▇▇▇, III
UNIPHY FOUNDERS
▇▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
The ▇▇▇▇▇▇▇ Irrevocable Trust, ▇▇▇ ▇▇▇▇▇▇▇, Trustee
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
H. ▇▇▇▇▇▇ ▇▇▇▇▇▇ III
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
EXHIBIT B
SHARES OWNED BY INVESTORS